USE OF PROGESTERONE RECEPTOR TREATMENT FOR THE TREATMENT OF STEROID-RESISTANT BREAST CANCER

• 1. 一种抗ErbB2抗体及其在治疗乳腺癌中的应用 [P] . 中国专利： CN111748037B . 2021.01.12
• 2. 一种抗ErbB2抗体及其在治疗乳腺癌中的应用 [P] . 中国专利： CN111748037A . 2020-10-09
• 3. USE OF PROGESTERONE RECEPTOR TREATMENT FOR THE TREATMENT OF STEROID-RESISTANT BREAST CANCER [P] . AT339208T . 2006-10-15

  机译： 孕激素受体治疗在抗类固醇乳腺癌中的应用

• 4. USE OF PROGESTERONE RECEPTOR INHIBITORS FOR TREATING STEROID-RESISTANT BREAST CANCER [P] . UA76128C2 . 2003-08-15

  机译： 使用孕激素受体抑制剂治疗抗类固醇乳腺癌

• 5. Targeted treatment for patients with estrogen receptor negative and progesterone receptor negative breast cancers [P] . 美国专利： US9314515B2 . 2016-04-19

  机译： 雌激素受体阴性和孕激素受体阴性乳腺癌患者的靶向治疗

• 1. Value of pre-treatment biomarkers in prediction of response to neoadjuvant endocrine therapy for hormone receptor-positive postmenopausal breast cancer [J] . Min Ying, Yingjian He, Meng Qi, 中国癌症研究（英文版） . 2013,第004期
• 2. Bi-directional Regulation of Human Progesterone Receptors and the Mitogen Activated Protein Kinase Pathway in Breast Cancer Cell Models [C] . Carol A. Lange, Emily Faivre, Ming Qi International Symposium on Hormonal Carcinogenesis . 2005
• 3. Progesterone receptor-A in taxane treatment of breast cancer. [D] . Badtke, Melanie M. 2010
• 4. Estrogen Receptor Progesterone Receptor Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer [O] . Richard S. Finn, Michael F. Press, Judy Dering, -1
• 5. Estrogen Receptor, Progesterone Receptor, Human Epidermal Growth Factor Receptor 2 (HER2), and Epidermal Growth Factor Receptor Expression and Benefit From Lapatinib in a Randomized Trial of Paclitaxel With Lapatinib or Placebo As First-Line Treatment in HER2-Negative or Unknown Metastatic Breast Cancer [O] . Finn, Richard S., Press, Michael F., Dering, Judy, 2009

• 1. CDK4/6 inhibitors in the treatment of hormone receptor-positive, HER2-negative advanced breast cancer [J] . Xue Yang . TMR药物联合治疗 . 2020,第001期
• 2. Targeting androgen receptor and trail: a novel treatment paradigm for breast cancer [J] . Ya-ping TU ,Yan XIE ,Peter W ABEL . 中国药理学与毒理学杂志 . 2017,第010期
• 3. Hormonal therapy might be a better choice as maintenance treatment than capecitabine after response to first-line capecitabine-based combination chemotherapy for patients with hormone receptor-positive and HER2-negative,metastatic breast cancer [J] . Xue-Lian Chen ,Feng Du ,Ruo-Xi Hong . 癌症 . 2016,第6期
• 4. Current medical treatment of estrogen receptor-positive breast cancer [J] . Franco Lumachi ,Davide A Santeufemia ,Stefano MM Basso . 世界生物化学杂志：英文版（电子版） . 2015,第3期
• 5. 试论“治未病”思想在乳腺癌术后抗复发转移治疗中的应用 [C] . 刘胜 ,孙霃平 ,花永强 . 2008年首届国际中西医肿瘤研究论坛 . 2008
• 6. 17β-羟类固醇脱氢酶2及孕激素受体B亚型在子宫内膜息肉中的表达及意义 [A] . 陈海霞 . 2011